Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
about
A perspective on anti-EGFR therapies targeting triple-negative breast cancerPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesVaricella-zoster virus (VZV) infection as a possible cause of Ogilvie's syndrome in an immunocompromised host.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.Bendamustine associated immune suppression and infections during therapy of hematological malignancies.Chronic Effects of Resistance Training in Breast Cancer Survivors.Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.Metastatic and triple-negative breast cancer: challenges and treatment optionsTriple-negative breast cancer and the potential for targeted therapy
P2860
Q28069867-CE3EB240-44B6-4327-BCA1-FA66AB7A1B5DQ28540830-51A93922-A2F4-4E01-AA5D-3F2187E41375Q33899992-0056B6ED-F425-4C07-8672-5D7D56C31D2CQ34441761-6BAC3712-E683-4E6A-B360-D316CFEBAF04Q36097941-A86B1CAD-82C6-4F8E-8596-7553AA0B5EADQ38676858-B7C8CEAD-3F40-4D30-B2B3-56E8DA4F5231Q41408572-5CB7E448-0D1F-46AD-B0AA-B72DBDE96E27Q43185836-2AE9AEE4-6566-4C83-A943-B893568A8A0DQ49887925-6564FA25-9812-48C7-9CB2-8B2EFCE00E36Q50455931-5237CD62-B73F-42BC-8B72-3549EC99CE9AQ57105258-99D01EC6-2D28-4E7B-B0E0-BFDDD682D0D6Q57115890-AC61C1FD-75CC-4AD8-B106-06E14546522B
P2860
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Severe and prolonged lymphopen ...... triple negative breast cancer
@en
Severe and prolonged lymphopen ...... triple negative breast cancer.
@nl
type
label
Severe and prolonged lymphopen ...... triple negative breast cancer
@en
Severe and prolonged lymphopen ...... triple negative breast cancer.
@nl
prefLabel
Severe and prolonged lymphopen ...... triple negative breast cancer
@en
Severe and prolonged lymphopen ...... triple negative breast cancer.
@nl
P2093
P2860
P1476
Severe and prolonged lymphopen ...... triple negative breast cancer
@en
P2093
Amy S Ruppert
Anissa Bingman
Bhuvaneswari Ramaswamy
Charles L Shapiro
Eric H Kraut
Ewa Mrozek
Maryam B Lustberg
Melinda Lynn
Rachel M Layman
Raquel Reinbolt
P2860
P2888
P304
P356
10.1007/S00280-013-2112-2
P577
2013-02-21T00:00:00Z